RAB39B and cask-related x-linked intellectual disability: While screening additional large cohorts will further test this hypothesis, longitudinal studies of individuals with XLID secondary to duplication and triplication of RAB39B (18, 19) will also inform whether an increased dosage of RAB39B can cause a parkinsonian phenotype.